Drug intelligence / Profile preview

GW842470X

Development stage: Phase 2
Lead developer: GSK
Modality: Small Molecules
Administration: Topical

Overview

GW842470X is a small molecule drug that acts as a phosphodiesterase 4 (PDE4) inhibitor. It was developed by GSK Plc and elbion NV for treating immune system diseases, including atopic dermatitis. The drug was primarily investigated for its anti-inflammatory properties.

Other names: GW842470X creamGW-842470X creamGW 842470X cream

Targets

PDE4 (Phosphodiesterase 4A1)

Beyond the preview

Go deeper on GW842470X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GW842470X.

Explore the full profile